KISQALI (ribociclib)

Key points

Favourable opinion for reimbursement in combination with fulvestrant in the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, in the absence of short-term life-threatening symptomatic visceral involvement, as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

What therapeutic improvement?

Therapeutic improvement compared to fulvestrant alone.

Role in the care pathway?

In the absence of short-term life-threatening symptomatic visceral involvement, the therapeutic strategy is based on endocrine therapy.

In postmenopausal women, treatment with non-steroidal aromatase inhibitors (letrozole or anastrozole) is recommended as a first-line treatment, unless they were previously administered as part of adjuvant therapy discontinued less than 12 months previously. The addition of a CDK4/6 inhibitor [IBRANCE (palbociclib), KISQALI (ribociclib) or VERZENIOS (abemaciclib)] to the aromatase inhibitor is recommended in current clinical practice guidelines. KISQALI (ribociclib) in combination with fulvestrant is also a treatment option in women diagnosed at the advanced stage or in relapse following adjuvant endocrine therapy. In the event of disease progression under endocrine therapy, the choice of treatment will depend primarily on the type of prior therapy, without the optimal endocrine therapy sequence having been clearly established. Following first-line therapy at an advanced stage combining an aromatase inhibitor and a CDK4/6 inhibitor, the treatments that may be proposed for second-line therapy are fulvestrant alone, tamoxifen or exemestane alone or in combination with everolimus. In the event of progression under endocrine therapy administered as monotherapy at an advanced stage, the co-administration of endocrine therapy, in particular with fulvestrant, with a CDK4/6 inhibitor is recommended8,9. The use of cytotoxic chemotherapy is an available option that should only be considered in the event of aggressive disease presentation.

Role of the medicinal product in the care pathway

Considering demonstration of the superiority of the addition of KISQALI (ribociclib) to fulvestrant compared to fulvestrant alone in terms of overall survival, co-administration of KISQALI (ribociclib) with fulvestrant is a treatment option to be favoured compared to fulvestrant alone in postmenopausal women with HR+ / HER2- locally advanced or metastatic breast cancer, without short-term life-threatening symptomatic visceral involvement, as first or second-line therapy, depending on prior treatments. 

CDK4/6 inhibitors in combination with endocrine therapy have an indication as both first and second-line treatment at the advanced stage. However, no data is available enabling the optimal treatment sequence to be established. There is no evidence of a clinical benefit of further treatment with a CDK 4/6 inhibitor for patients having already received one in a previous line of treatment.

The choice of CDK4/6 inhibitor to be used in combination with fulvestrant between IBRANCE (palbociclib), VERZENIOS (abemaciclib) and KISQALI (ribociclib), should take into account, in particular, the level of evidence of the demonstration in terms of efficacy as well as the safety profile of each medicinal product.

The decision to prescribe KISQALI (ribociclib) should take into account demonstration of an improvement in overall survival compared to fulvestrant alone, as well as its hepatic, cardiac and haematological safety profile.